| Literature DB >> 32888499 |
Jing Zhang1, Liqiang Fu2, Bin Shen1, Yingtao Liu2, Wenqian Wang1, Xin Cai3, Linglong Kong2, Yilin Yan3, Ryan Meng4, Zhuming Zhang5, Ying-Nan P Chen1, Qian Liu2, Zhao-Kui Wan2, Tianyuan Zhou1, Xiaotao Wang3, Paul Gavine1, Amanda Del Rosario5, Kay Ahn5, Ulrike Philippar6, Ricardo Attar5, Jennifer Yang1, Yanping Xu2, James P Edwards5, Xuedong Dai7.
Abstract
The interleukin-1 receptor-activated kinase 4 (IRAK4) belongs to the IRAK family of serine/threonine kinases and plays a central role in the innate immune response. However, the function of IRAK4 in tumor growth and progression remains elusive. Here we sought to determine the enzymatic and scaffolding functions of IRAK4 in activated B-cell-like diffuse large B cell lymphoma (ABC DLBCL). We chose a highly selective IRAK4 kinase inhibitor to probe the biological effects of kinase inhibition and developed a series of IRAK4 degraders to evaluate the effects of protein degradation in ABC DLBCL cells. Interestingly, the results demonstrated that neither IRAK4 kinase inhibition nor protein degradation led to cell death or growth inhibition, suggesting a redundant role for IRAK4 in ABC DLBCL cell survival. IRAK4 degraders characterized in this study provide useful tools for understanding IRAK4 protein scaffolding function, which was previously unachievable using pharmacological perturbation.Entities:
Keywords: ABC DLBCL; IRAK4 PROTAC; MyD88; PROTAC; activated B-cell-like diffuse large B cell lymphoma; interleukin-1 receptor activated kinase 4 (IRAK4); myeloid differentiation primary response 88 signaling; proteolysis-targeting chimera; scaffolding activity of IRAK4; selective IRAK4 degrader
Mesh:
Substances:
Year: 2020 PMID: 32888499 DOI: 10.1016/j.chembiol.2020.08.010
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116